Clinical trial • Phase I • Cardiology|Respiratory
Valproic acid for Pulmonary hypertension | Idiopathic pulmonary fibrosis | Cardiopulmonary disease
Phase I trial of Valproic acid for Pulmonary hypertension | Idiopathic pulmonary fibrosis | Cardiopulmonary disease.
Overview
- Trial Therapeutic Area
- Cardiology|Respiratory
- Trial Disease
- Pulmonary hypertension | Idiopathic pulmonary fibrosis | Cardiopulmonary disease
- Trial Stage
- Phase I
- Drug Modality
- Small molecule
Key dates
- Initial CTIS Submission Date
- 29-01-2026
- First CTIS Authorization Date
- 17-03-2026
Trial design
Randomised, open-label, valproic acid (comparator) - dose and schedule not specified; cs014 (investigational) - dose and schedule not specified.-controlled, crossover Phase I trial across 1 site in Sweden.
- Randomised
- Yes
- Open Label
- Yes
- Comparator
- Valproic acid (comparator) - dose and schedule not specified; CS014 (investigational) - dose and schedule not specified.
- Crossover
- Yes
- Target Sample Size
- 14
Recruitment
- Planned Sample Size
- 14
- Recruitment Window Months
- 1
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 14
Sweden
- Earliest CTIS Part Ii Submission Date
- 06-03-2026
- Latest Decision Or Authorization Date
- 17-03-2026
- Processing Time Days
- 11
- Number Of Sites
- 1
- Number Of Participants
- 14
Sites
- Site Name
- CTC Clinical Trial Consultants AB
- Department Name
- CTC
- Contact Person Name
- Johan Nilsson
- Contact Person Email
- johan.nilsson@ctc-ab.se
Sponsor
Primary sponsor
- Full Name
- Cereno Scientific AB
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Sweden
Investigational products
- Investigational Product Name
- CS014
- Modality
- Small molecule
- Routes Of Administration
- oral
- Route
- oral
- Investigational Product Name
- Valproic acid
- Active Substance
- Valproic acid
- Modality
- Small molecule
- Routes Of Administration
- oral
- Route
- oral
Related trials
Other published trials that may interest you.
- ARGATROBAN MONOHYDRATE for Respiratory failure|Heart failure
- EDOXABAN for Chronic thromboembolic pulmonary hypertension (CTEPH)|Chronic thromboembolic disease (CTED) without pulmonary hypertension
- MOSLICIGUAT for Pulmonary hypertension associated with interstitial lung disease
- Isoflurane for Cardiogenic shock